Transcription of 新しい変形性膝関節症の治療 ... - hakatara.net
1 1 OARSI OARSI ( ) OARSI: Osteoarthritis Research Society International OA , Osteoarthritis and Cartilage (OA) . OA 50 . OARSI 2005 9 OA OARSI 6 ( ) 4 2 11 1 EBM 2 16 OA.
2 (SOR) . (SOR) SOR ( ) . OARSI .OARSI 95 CI . 25 22 SOR SOR SOR ( ) 2 , , , , , , , , , 1 OA.
3 SOR 96 (95 CI 93 99) SOR 94 (95 CI 87 99) A OA 12 12 (100 ) 100 SOR 2. OA . SOR 97 (95 CI 95 99) SOR 97 (95 CI 94 99) A 2 MA(LoE Ia) ES . (LoE IV) RCT (LoE Ib) 3. OA.
4 SOR 66 (95 CI 57 75) SOR 58 (95 CI 52 64) C OA 1 1 439 RCT ES ES 4. OA , . SOR 89 (95 CI 82 96) SOR 86 (95 CI 82 90) B (LoE IV) (100 ) 5 5 . OA , 3 RCT 1 QOL (8 ) . 4 1 WOMAC.
5 1 (LoE Ib). 3 5. OA . SOR 96 (95 CI 93 99) SOR 94 (95 CI 88 100) A OA 21 21 13 RCT MA(LoE Ia) pooled ES ( ) ( ) . 6. OA . SOR 96 (95 CI 92 100) SOR 96 (95 CI 93 98) A (100 ) 14 13 . 2006 31 2 RCT(LoE Ib) OA 8 ES ES WOMAC 50 NTT 3(95 CI 2 9) 454 OA 4 RCT MA (LoE Ia).
6 ( ) pooled ES ( ). 5 / 7. OA / . SOR 90 (95 CI 84 96) SOR 94 (95 CI 91 97) A RCT , OA (LoE IV) / 100 OA OA 40 OA 11 11 8. OA . SOR 76 (95 CI 69 83) SOR 76 (95 CI 72 79) B Cochrane (LoE Ia) RCT 6 WOMAC 9 8 9.
7 OA OA OA . SOR 77 (95 CI 66-88) SOR 81 (95 CI 76 85) B OA 13 12 OA 4 lateral thrust 3 3 RCT OA 156 RCT 6 50 2 51 WOMAC NSAIDs , (LoE Ia). 2 . OA (LoE IV) OA 10 OA.
8 SOR 64 (95 CI 60 88) SOR 63 (95 CI 54 71) C / OA / 10 7 1 2 . (LoE Ia) OA 100 RCT OA 2 (15 ) (17 ) 1 RCT 2 20 5 2 , 29 . 3 3 3 3 . 11. (TENS) OA . SOR 58 (95 CI 45 72) SOR 46 (95 CI 37 55) C TENS 10 8 2000 Cochrane 2004 (LoE Ia).
9 OA 2 4 TENS 425 7 RCT MA . TENS TENS . 12. OA (NSAIDs) (GI) COX-2 NSAIDs CV COX-2 ,NSAIDs . SOR 93 (95 CI 88 99) SOR 92 (95 CI 90 95) A NSAIDs PPI 8 8 COX-2 11 11 . NSAIDs , OA (LoE Ia). 10,000 OA 2 COX-2 NSAIDs 23 RCT MA(2004 ) ES NSAIDs , RCT MA(2004 ) (ES ).
10 (RR ) NSAIDs (RR ). ES . 5 NSAIDs . 2004 MA NSAIDs GI (RR ) RCT Cochrane (RR ). NSAIDs (PUBs) GI . 4,431 16 MA NSAIDs OR 25,732 23 PUBs OR . 750,000 9 PUBs pooled RR . GI COX-2 NSAIDs PPI 75,000 112 RCT (LoE Ia).
